Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Dermatology

Free Subscription Articles published in Lancet Retrieve available abstracts of 157 articles: HTML format

Single Articles

July 2021
1. CORTES J, Rugo HS, Guo Z, Karantza V, et al
   Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
   Lancet. 2021;398:24-25.
   PubMed    
   
   
   
2. MASUDA J, Ozaki Y, Hara F, Kitano S, et al
   Pembrolizumab plus chemotherapy in triple-negative breast cancer.
   Lancet. 2021;398:24.
   PubMed    
   
   
   May 2021
3. REICH K, Teixeira HD, de Bruin-Weller M, Bieber T, et al
   Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
   Lancet. 2021 May 20. pii: S0140-6736(21)00589.
   PubMed     Abstract available
   
   
   
4. GUTTMAN-YASSKY E, Teixeira HD, Simpson EL, Papp KA, et al
   Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
   Lancet. 2021 May 20. pii: S0140-6736(21)00588.
   PubMed     Abstract available
   
   
   
5. THYSSEN JP, Thomsen SF
   Treatment of atopic dermatitis with biologics and Janus kinase inhibitors.
   Lancet. 2021 May 20. pii: S0140-6736(21)00717.
   PubMed    
   
   
   April 2021
6. RUBEL D
   Nanobody cytokine blockers in psoriasis.
   Lancet. 2021;397:1523-1524.
   PubMed    
   
   
   
7. PAPP KA, Weinberg MA, Morris A, Reich K, et al
   IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
   Lancet. 2021;397:1564-1575.
   PubMed     Abstract available
   
   
   
8. GRIFFITHS CEM, Armstrong AW, Gudjonsson JE, Barker JNWN, et al
   Psoriasis.
   Lancet. 2021;397:1301-1315.
   PubMed     Abstract available
   
   
   February 2021
9. LAMBRECHTS RA, Uyttenboogaart M, Drost G
   A vertebral artery halo sign indicates giant cell arteritis affecting the posterior circulation of the brain.
   Lancet. 2021;397:e6.
   PubMed    
   
   
   
10. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    PubMed     Abstract available
    
    
    
11. REICH K, Papp KA, Blauvelt A, Langley RG, et al
    Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Lancet. 2021;397:487-498.
    PubMed     Abstract available
    
    
    
12. GORDON KB, Foley P, Krueger JG, Pinter A, et al
    Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Lancet. 2021;397:475-486.
    PubMed     Abstract available
    
    
    
13. HUANG WW, Feldman SR
    The next quantum leap forward? Bimekizumab for psoriasis.
    Lancet. 2021;397:446-448.
    PubMed    
    
    
    January 2021
14. HUDOWENZ O, Klemm P, Lange U, Mueller-Ladner U, et al
    Widespread soft tissue calcification in systemic sclerosis, polymyositis, and polyarthritis.
    Lancet. 2021;397:409.
    PubMed    
    
    
    
15. GHORESCHI K, Balato A, Enerback C, Sabat R, et al
    Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.
    Lancet. 2021 Jan 27. pii: S0140-6736(21)00184.
    PubMed     Abstract available
    
    
    
16. CHEN L, Zhou M
    Must be sympathetic nervous system with unilateral facial flushing in harlequin syndrome.
    Lancet. 2021;397:318.
    PubMed    
    
    
    
17. SIMPSON EL, Bieber T, Thyssen JP, Valdez H, et al
    Abrocitinib for atopic dermatitis - Authors' reply.
    Lancet. 2021;397:196.
    PubMed    
    
    
    
18. UPPAL SK, Chat VS, Kearns DG, Wu JJ, et al
    Abrocitinib for atopic dermatitis.
    Lancet. 2021;397:195-196.
    PubMed    
    
    
    
19. CHAKRABORTY U, Chandra A
    Bitot's spots, dry eyes, and night blindness indicate vitamin A deficiency.
    Lancet. 2021;397:e2.
    PubMed    
    
    
    December 2020
20. LLEO A, Wang GQ, Gershwin ME, Hirschfield GM, et al
    Primary biliary cholangitis.
    Lancet. 2020;396:1915-1926.
    PubMed     Abstract available
    
    
    
21. LAI VWY, Meher-Homji Z, Liu F, Sasadeusz J, et al
    Primary herpes simplex virus type 2 hepatitis diagnosed during laparoscopy.
    Lancet. 2020;396:e90.
    PubMed    
    
    
    
22. CORTES J, Cescon DW, Rugo HS, Nowecki Z, et al
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Lancet. 2020;396:1817-1828.
    PubMed     Abstract available
    
    
    November 2020
23. ROSMARIN D, Butler K, Kuo F, Harris JE, et al
    Ruxolitinib cream for the treatment of vitiligo - Authors' reply.
    Lancet. 2020;396:1736.
    PubMed    
    
    
    
24. UPPAL SK, Kearns DG, Chat VS, Wu JJ, et al
    Ruxolitinib cream for the treatment of vitiligo.
    Lancet. 2020;396:1735-1736.
    PubMed    
    
    
    
25. MCCLELLAND S 3RD
    Breast cancer radiation therapy.
    Lancet. 2020;396:1559.
    PubMed    
    
    
    
26. BRUNT AM, Haviland JS, Wheatley DA, Yarnold JR, et al
    Breast cancer radiation therapy - Authors' reply.
    Lancet. 2020;396:1559-1560.
    PubMed    
    
    
    
27. OFFERSEN BV, Overgaard J
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558.
    PubMed    
    
    
    
28. DOUEK M, De Silva-Minor S, Davies L, Jones B, et al
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558-1559.
    PubMed    
    
    
    October 2020
29. UDOMKARNJANANUN S, Puapatanakul P, Praditpornsilpa K
    Relapsing polychondritis associated with pauci-immune crescentic glomerulonephritis.
    Lancet. 2020;396:e63.
    PubMed    
    
    
    September 2020
30. OZPOLAT HT, Baran B, Akyuz F
    Skin lesions indicate cause of acute gastrointestinal bleeding: neurofibromatosis type 1.
    Lancet. 2020;396:e52.
    PubMed    
    
    
    
31. STERGIOU IE, Christoforou P, Sypsa G, Skoufias S, et al
    Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia.
    Lancet. 2020;396:853.
    PubMed    
    
    
    
32. DI COSIMO S
    Advancing immunotherapy for early-stage triple-negative breast cancer.
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31962.
    PubMed    
    
    
    
33. MITTENDORF EA, Zhang H, Barrios CH, Saji S, et al
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31953.
    PubMed     Abstract available
    
    
    
34. ABIGNANO G, Mennillo GA, Lettieri G
    Foot ulcers in systemic sclerosis escape surgical amputation.
    Lancet. 2020;396:e29.
    PubMed    
    
    
    August 2020
35. CARDENAS-DE LA GARZA JA, Esquivel-Valerio JA, Arvizu-Rivera RI, Colunga-Pedraza PR, et al
    Flushing out a plasmacytoma in a patient with POEMS and AESOP syndromes.
    Lancet. 2020;396:e21.
    PubMed    
    
    
    
36. FREITAS PFS, Oliveira JM, Kater CE
    Crisis? What crisis? Abdominal pain and darkening skin in Addison's disease.
    Lancet. 2020;396:498.
    PubMed    
    
    
    
37. JAMIOLKOWSKI D, Muhleisen B, Muller S, Navarini AA, et al
    SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report.
    Lancet. 2020 Aug 13. pii: S0140-6736(20)31754.
    PubMed    
    
    
    
38. LANGAN SM, Irvine AD, Weidinger S
    Atopic dermatitis.
    Lancet. 2020;396:345-360.
    PubMed     Abstract available
    
    
    July 2020
39. SIMPSON EL, Sinclair R, Forman S, Wollenberg A, et al
    Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2020;396:255-266.
    PubMed     Abstract available
    
    
    
40. WEIDINGER S, Schreiber S
    Abrocitinib for atopic dermatitis: a step forward.
    Lancet. 2020;396:215-217.
    PubMed    
    
    
    
41. OBASI AI
    Equity in excellence or just another tax on Black skin?
    Lancet. 2020 Jul 23. pii: S0140-6736(20)31536.
    PubMed    
    
    
    
42. LAM RPK, Wong KW, Wan CK
    Allergic contact dermatitis and tracheobronchitis associated with repeated exposure to tear gas.
    Lancet. 2020 Jul 13. pii: S0140-6736(20)31560.
    PubMed    
    
    
    
43. PASSERON T
    First step in a new era for treatment of patients with vitiligo.
    Lancet. 2020;396:74-75.
    PubMed    
    
    
    
44. ROSMARIN D, Pandya AG, Lebwohl M, Grimes P, et al
    Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Lancet. 2020;396:110-120.
    PubMed     Abstract available
    
    
    
45. SHAIGANY S, Gnirke M, Guttmann A, Chong H, et al
    An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19.
    Lancet. 2020 Jul 10. pii: S0140-6736(20)31526.
    PubMed    
    
    
    
46. GINSBURG O, Horton R
    A Lancet Commission on women and cancer.
    Lancet. 2020;396:11-13.
    PubMed    
    
    
    June 2020
47. ALLEN S, Cortina CS
    An unusual cause of breast hypertrophy: pseudoangiomatous stromal hyperplasia secondary to contraceptive implant.
    Lancet. 2020;395:1937.
    PubMed    
    
    
    
48. GUTZMER R, Stroyakovskiy D, Gogas H, Robert C, et al
    Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2020;395:1835-1844.
    PubMed     Abstract available
    
    
    
49. RIBAS A
    Triple therapy for BRAF(V600)-mutated melanoma.
    Lancet. 2020;395:1814-1815.
    PubMed    
    
    
    
50. AHMED MA, Abdelnabi M, Almaghraby A, Elkafrawy FR, et al
    Neuropathy, encephalopathy, status epilepticus, and acute intermittent porphyria.
    Lancet. 2020;395:e101.
    PubMed    
    
    
    May 2020
51. MURRAY BRUNT A, Haviland JS, Wheatley DA, Sydenham MA, et al
    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
    Lancet. 2020;395:1613-1626.
    PubMed     Abstract available
    
    
    
52. ZIMMER L, Livingstone E, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2020;395:1558-1568.
    PubMed     Abstract available
    
    
    
53. SULLIVAN RJ
    Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
    Lancet. 2020;395:1524-1525.
    PubMed    
    
    
    
54. VERDONI L, Mazza A, Gervasoni A, Martelli L, et al
    An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.
    Lancet. 2020 May 13. pii: S0140-6736(20)31103.
    PubMed     Abstract available
    
    
    
55. HETLAND ML
    Psoriatic arthritis: still room for improvement.
    Lancet. 2020;395:1463-1465.
    PubMed    
    
    
    
56. MCINNES IB, Behrens F, Mease PJ, Kavanaugh A, et al
    Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    Lancet. 2020;395:1496-1505.
    PubMed     Abstract available
    
    
    April 2020
57. JOHNSON PDR
    Buruli ulcer: cured by 8 weeks of oral antibiotics?
    Lancet. 2020;395:1231-1232.
    PubMed    
    
    
    
58. PHILLIPS RO, Robert J, Abass KM, Thompson W, et al
    Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
    Lancet. 2020;395:1259-1267.
    PubMed     Abstract available
    
    
    
59. KERSCHBAUMER A, Aletaha D
    Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?
    Lancet. 2020;395:1091-1093.
    PubMed    
    
    
    
60. MEASE PJ, Rahman P, Gottlieb AB, Kollmeier AP, et al
    Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Lancet. 2020;395:1126-1136.
    PubMed     Abstract available
    
    
    
61. DEODHAR A, Helliwell PS, Boehncke WH, Kollmeier AP, et al
    Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Lancet. 2020;395:1115-1125.
    PubMed     Abstract available
    
    
    March 2020
62. BOUJAN N, Geraud C
    Neuropsychiatric symptoms, skin disease, and weight loss: necrolytic migratory erythema and a glucagonoma.
    Lancet. 2020;395:985.
    PubMed    
    
    
    
63. SPRING LM, Wander SA, Andre F, Moy B, et al
    Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
    Lancet. 2020;395:817-827.
    PubMed     Abstract available
    
    
    
64. KROWN SE, Moser CB, MacPhail P, Matining RM, et al
    Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
    Lancet. 2020 Mar 5. pii: S0140-6736(19)33222.
    PubMed     Abstract available
    
    
    
65. FREEMAN EE, McMahon DE, Laker-Oketta M
    Time to address disparities in the standard of care for Kaposi sarcoma.
    Lancet. 2020 Mar 5. pii: S0140-6736(20)30473.
    PubMed    
    
    
    February 2020
66. DESGRANGES F, Coste AT, Wernly D, Dufour J, et al
    Immunosuppressed gardener pricked by roses grows Legionella longbeachae.
    Lancet. 2020;395:604.
    PubMed    
    
    
    
67. PERRETT KP, Peters RL
    Emollients for prevention of atopic dermatitis in infancy.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)33174.
    PubMed    
    
    
    
68. SKJERVEN HO, Rehbinder EM, Vettukattil R, LeBlanc M, et al
    Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)32983.
    PubMed     Abstract available
    
    
    
69. CHALMERS JR, Haines RH, Bradshaw LE, Montgomery AA, et al
    Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)32984.
    PubMed     Abstract available
    
    
    
70. EARL HM, Hiller L, Plummer C, Miles D, et al
    Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
    Lancet. 2020;395:492-493.
    PubMed    
    
    
    
71. GUO S, Tse G, Liu T
    Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Lancet. 2020;395:491-492.
    PubMed    
    
    
    
72. NASH P
    Inhibition of interleukins 17A and 17F in psoriatic arthritis.
    Lancet. 2020;395:395-396.
    PubMed    
    
    
    
73. LANE R
    Geraldine McGinty: leading light in US radiology.
    Lancet. 2020;395:407.
    PubMed    
    
    
    
74. RITCHLIN CT, Kavanaugh A, Merola JF, Schett G, et al
    Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
    Lancet. 2020;395:427-440.
    PubMed     Abstract available
    
    
    January 2020
75. CHUMSRI S, Thompson EA
    Carryover effects of aromatase inhibitors in prevention.
    Lancet. 2020;395:91-92.
    PubMed    
    
    
    
76. THE LANCET
    Biosimilars: a new era in access to breast cancer treatment.
    Lancet. 2020;395:2.
    PubMed    
    
    
    December 2019
77. COLES CE, Bliss JM, Poortmans PM
    Accelerated partial breast irradiation: more questions than answers?
    Lancet. 2019;394:2127-2129.
    PubMed    
    
    
    
78. CUZICK J, Sestak I, Forbes JF, Dowsett M, et al
    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
    Lancet. 2019 Dec 11. pii: S0140-6736(19)32955.
    PubMed     Abstract available
    
    
    
79. STIENSTRA Y, Beeres DT, Phillips R, Vonk M, et al
    The public health control of scabies: priorities for research and action.
    Lancet. 2019;394:2068.
    PubMed    
    
    
    
80. MIDDLETON J, Walker SL, House T, Head MG, et al
    Ivermectin for the control of scabies outbreaks in the UK.
    Lancet. 2019;394:2068-2069.
    PubMed    
    
    
    
81. VICINI FA, Cecchini RS, White JR, Arthur DW, et al
    Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32514.
    PubMed     Abstract available
    
    
    
82. WHELAN TJ, Julian JA, Berrang TS, Kim DH, et al
    External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32515.
    PubMed     Abstract available
    
    
    October 2019
83. THANGARAJU P, Venkatesan S
    A double blow for a patient with leprosy: a reversal reaction and an adverse drug reaction.
    Lancet. 2019;394:1450.
    PubMed    
    
    
    
84. ABDALLAH FW, Wijeysundera DN
    Anaesthetic interventions and long-term tumour recurrence.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32314.
    PubMed    
    
    
    
85. SESSLER DI, Pei L, Huang Y, Fleischmann E, et al
    Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32313.
    PubMed     Abstract available
    
    
    
86. BRUINSTROOP E, Cairo I, Drillenburg P, van Dam PS, et al
    Hypothyroidism to Graves' disease and late appearance of pretibial myxoedema.
    Lancet. 2019;394:1364.
    PubMed    
    
    
    September 2019
87. SCHMIDT E, Kasperkiewicz M, Joly P
    Pemphigus.
    Lancet. 2019;394:882-894.
    PubMed     Abstract available
    
    
    
88. CHAYED Z, Kamaleswaran S, Bygum A
    A spot diagnosis! Aplasia cutis congenita in monozygotic twins.
    Lancet. 2019;394:868.
    PubMed    
    
    
    August 2019
89. BERAL V, Peto R, Pirie K, Reeves G, et al
    Menopausal hormone therapy and 20-year breast cancer mortality.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)32033.
    PubMed    
    
    
    
90. 
    Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31709.
    PubMed     Abstract available
    
    
    
91. KOTSOPOULOS J
    Menopausal hormones: definitive evidence for breast cancer.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31901.
    PubMed    
    
    
    
92. NAKKAZI E
    People with albinism in Africa: contending with skin cancer.
    Lancet. 2019;394:553-554.
    PubMed    
    
    
    
93. REICH K, Armstrong AW, Langley RG, Flavin S, et al
    Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Lancet. 2019 Aug 8. pii: S0140-6736(19)31773.
    PubMed     Abstract available
    
    
    
94. MAHIL SK, Smith CH
    Psoriasis biologics: a new era of choice.
    Lancet. 2019 Aug 8. pii: S0140-6736(19)31772.
    PubMed    
    
    
    
95. CHAPPELL LC, Bell JL, Smith A, Linsell L, et al
    Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
    Lancet. 2019 Aug 1. pii: S0140-6736(19)31270.
    PubMed     Abstract available
    
    
    July 2019
96. ENGELMAN D, Cantey PT, Marks M, Solomon AW, et al
    The public health control of scabies: priorities for research and action.
    Lancet. 2019;394:81-92.
    PubMed     Abstract available
    
    
    
97. THOMPSON JF, Friedman EB
    Appropriate excision margins for cutaneous melanomas.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31272.
    PubMed    
    
    
    
98. LEBWOHL M
    Interleukin-23 blockade: another breakthrough in the treatment of psoriasis.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31513.
    PubMed    
    
    
    
99. REICH K, Gooderham M, Thaci D, Crowley JJ, et al
    Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)30952.
    PubMed     Abstract available
    
    
    
100. UTJES D, Malmstedt J, Teras J, Drzewiecki K, et al
     2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.
     Lancet. 2019 Jul 4. pii: S0140-6736(19)31132.
     PubMed     Abstract available
     
     
     June 2019
101. HURVITZ SA
     Is the duration of adjuvant trastuzumab debate still clinically relevant?
     Lancet. 2019;393:2565-2567.
     PubMed    
     
     
     
102. DROLET M, Benard E, Perez N, Brisson M, et al
     Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
     Lancet. 2019 Jun 26. pii: S0140-6736(19)30298.
     PubMed     Abstract available
     
     
     
103. QIAN YT, Ma DL
     Atypical presentation of classic Kaposi's sarcoma.
     Lancet. 2019;393:2521.
     PubMed    
     
     
     
104. PIVOT X, Romieu G, Debled M, Pierga JY, et al
     6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
     Lancet. 2019 Jun 6. pii: S0140-6736(19)30653.
     PubMed     Abstract available
     
     
     
105. EARL HM, Hiller L, Vallier AL, Loi S, et al
     6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
     Lancet. 2019 Jun 6. pii: S0140-6736(19)30650.
     PubMed     Abstract available
     
     
     March 2019
106. MCCRINDLE BW, Rowley AH
     Improving coronary artery outcomes for children with Kawasaki disease.
     Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.
     PubMed    
     
     
     
107. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
     Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
     Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
     PubMed     Abstract available
     
     
     
108. ABDOLI A
     Leishmaniasis.
     Lancet. 2019;393:872.
     PubMed    
     
     
     
109. BURZA S, Croft SL, Boelaert M
     Leishmaniasis - Authors' reply.
     Lancet. 2019;393:872-873.
     PubMed    
     
     
     
110. DEPAQUIT J, Gay F, Kaltenbach ML
     Leishmaniasis.
     Lancet. 2019;393:871-872.
     PubMed    
     
     
     
111. SAURABH S
     Leishmaniasis.
     Lancet. 2019;393:871.
     PubMed    
     
     
     February 2019
112. MUTEBI M
     Africa rising: gendered journeys of women patients and providers.
     Lancet. 2019;393:517-518.
     PubMed    
     
     
     
113. HURVITZ SA
     Dose intensification of chemotherapy for early breast cancer in the age of de-escalation.
     Lancet. 2019 Feb 7. pii: S0140-6736(19)30197.
     PubMed    
     
     
     
114. 
     Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
     Lancet. 2019 Feb 7. pii: S0140-6736(18)33137.
     PubMed     Abstract available
     
     
     
115. MOSE KF, Bygum A
     Chinese herbal remedy found to contain steroids and antifungals.
     Lancet. 2019;393:446.
     PubMed    
     
     
     January 2019
116. GILHAR A, Keren A, Paus R
     JAK inhibitors and alopecia areata.
     Lancet. 2019;393:318-319.
     PubMed    
     
     
     
117. POWER SP, O'Mahony D
     Diffuse large vessel giant cell arteritis found by (18)Fluorodeoxyglucose PET/CT imaging.
     Lancet. 2019;393:349.
     PubMed    
     
     
     December 2018
118. CAMERON DA, Gelber RD, Procter M, Suter T, et al
     Concerns about cardiotoxicity in the HERA trial - Authors' reply.
     Lancet. 2018;390:2767-2768.
     PubMed    
     
     
     
119. LEVY A, Chargari C, Deutsch E, Rivera S, et al
     Concerns about cardiotoxicity in the HERA trial.
     Lancet. 2018;390:2767.
     PubMed    
     
     
     
120. MEASE P, Coates LC, Helliwell PS, Stanislavchuk M, et al
     Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
     Lancet. 2018;392:2367-2377.
     PubMed     Abstract available
     
     
     October 2018
121. MAYA Y, Tashimo A, Ota M
     Persistent red and swollen eyelids.
     Lancet. 2018;392:1552.
     PubMed    
     
     
     
122. COSTEDOAT-CHALUMEAU N, Houssiau FA
     Ustekinumab: a promising new drug for SLE?
     Lancet. 2018;392:1284-1286.
     PubMed    
     
     
     
123. BOUSSINESQ M
     A new powerful drug to combat river blindness.
     Lancet. 2018;392:1170-1172.
     PubMed    
     
     
     
124. OPOKU NO, Bakajika DK, Kanza EM, Howard H, et al
     Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
     Lancet. 2018;392:1207-1216.
     PubMed     Abstract available
     
     
     September 2018
125. SCHADENDORF D, van Akkooi ACJ, Berking C, Griewank KG, et al
     Melanoma.
     Lancet. 2018;392:971-984.
     PubMed     Abstract available
     
     
     
126. LEBWOHL B, Sanders DS, Green PH
     Coeliac disease and dermatitis herpetiformis - Authors' reply.
     Lancet. 2018;392:917.
     PubMed    
     
     
     
127. RODRIGUES F, Bachmeyer C
     Coeliac disease and dermatitis herpetiformis.
     Lancet. 2018;392:916.
     PubMed    
     
     
     
128. CAIO G, De Giorgio R, Volta U
     Coeliac disease and dermatitis herpetiformis.
     Lancet. 2018;392:916-917.
     PubMed    
     
     
     
129. JANARTHANAN M, Rathinasamy J
     Aortic calcification in longstanding, undiagnosed Takayasu arteritis.
     Lancet. 2018;392:950.
     PubMed    
     
     
     August 2018
130. LA PLACA M, Chessa MA
     Erythema multiforme major with swollen lips and crusted erosions.
     Lancet. 2018;392:592.
     PubMed    
     
     
     
131. BURZA S, Croft SL, Boelaert M
     Leishmaniasis.
     Lancet. 2018 Aug 17. pii: S0140-6736(18)31204.
     PubMed     Abstract available
     
     
     
132. WILLER H
     Breast cancer in Venezuela: back to the 20th century.
     Lancet. 2018;392:461-462.
     PubMed    
     
     
     
133. CLINE A, Feldman SR
     Risankizumab for psoriasis.
     Lancet. 2018 Aug 7. pii: S0140-6736(18)31781.
     PubMed    
     
     
     
134. GORDON KB, Strober B, Lebwohl M, Augustin M, et al
     Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
     Lancet. 2018 Aug 7. pii: S0140-6736(18)31713.
     PubMed     Abstract available
     
     
     July 2018
135. WALLACE DJ, Furie RA, Tanaka Y, Kalunian KC, et al
     Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
     Lancet. 2018;392:222-231.
     PubMed     Abstract available
     
     
     June 2018
136. LIU XK, Li J
     Acral lentiginous melanoma.
     Lancet. 2018;391:e21.
     PubMed    
     
     
     
137. SHEIKH S, Sasieni P
     When should the errors in the UK's breast screening programme have been spotted?
     Lancet. 2018;391:2319-2320.
     PubMed    
     
     
     
138. DEODHAR A, Gottlieb AB, Boehncke WH, Dong B, et al
     Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
     Lancet. 2018;391:2213-2224.
     PubMed     Abstract available
     
     
     
139. NASH P
     Psoriatic arthritis: novel targets add to a therapeutic renaissance.
     Lancet. 2018;391:2187-2189.
     PubMed    
     
     
     
140. THE LANCET
     Psoriatic arthritis: classification and holistic management.
     Lancet. 2018;391:2185.
     PubMed    
     
     
     
141. VAN DEN BOSCH F, Coates L
     Clinical management of psoriatic arthritis.
     Lancet. 2018;391:2285-2294.
     PubMed     Abstract available
     
     
     
142. VEALE DJ, Fearon U
     The pathogenesis of psoriatic arthritis.
     Lancet. 2018;391:2273-2284.
     PubMed     Abstract available
     
     
     
143. ZOU Y, Hu W, Zheng J, Pan M, et al
     Nail infestation: an atypical presentation of typical scabies.
     Lancet. 2018;391:2272.
     PubMed    
     
     
     April 2018
144. MITJA O, Godornes C, Houinei W, Kapa A, et al
     Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study.
     Lancet. 2018;391:1599-1607.
     PubMed     Abstract available
     
     
     
145. RIEDL MA, Relan A, Harper JR, Cicardi M, et al
     C1 esterase inhibitor concentrates and attenuated androgens - Authors' reply.
     Lancet. 2018;391:1356.
     PubMed    
     
     
     
146. MULLER YD, Harr T, Dayer E, Seebach JD, et al
     C1 esterase inhibitor concentrates and attenuated androgens.
     Lancet. 2018;391:1355-1356.
     PubMed    
     
     
     February 2018
147. SMAJS D, Pospisilova P
     Macrolide resistance in yaws.
     Lancet. 2018 Feb 7. pii: S0140-6736(18)30205.
     PubMed    
     
     
     January 2018
148. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
     Targeted radiotherapy for early breast cancer.
     Lancet. 2018;391:26-27.
     PubMed    
     
     
     October 2017
149. AERTS O, Herman A, Bruze M, Goossens A, et al
     FreeStyle Libre: contact irritation versus contact allergy.
     Lancet. 2017;390:1644.
     PubMed    
     
     
     July 2017
150. SCHMITT AR, Wetter DA, Camilleri MJ, Khan SP, et al
     Langerhans cell histiocytosis presenting as a blueberry muffin rash.
     Lancet. 2017;390:155.
     PubMed    
     
     
     June 2017
151. MEASE P
     New pathways of treatment for psoriatic arthritis.
     Lancet. 2017;389:2268-2270.
     PubMed    
     
     
     February 2017
152. SPECHT JM, Davidson NE
     Optimal duration of trastuzumab for early HER2-positive breast cancer.
     Lancet. 2017 Feb 16. pii: S0140-6736(17)30322.
     PubMed    
     
     
     
153. CAMERON D, Piccart-Gebhart MJ, Gelber RD, Procter M, et al
     11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
     Lancet. 2017 Feb 16. pii: S0140-6736(16)32616.
     PubMed     Abstract available
     
     
     
154. PARES A
     An appealing new agent for treating cholestatic pruritus.
     Lancet. 2017 Feb 7. pii: S0140-6736(17)30320.
     PubMed    
     
     
     
155. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
     Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
     Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
     PubMed     Abstract available
     
     
     December 2016
156. NATSUME O, Kabashima S, Nakazato J, Yamamoto-Hanada K, et al
     Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial.
     Lancet. 2016 Dec 7. pii: S0140-6736(16)31418.
     PubMed     Abstract available
     
     
     November 2016
157. HARBECK N, Gnant M
     Breast cancer.
     Lancet. 2016 Nov 16. pii: S0140-6736(16)31891.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: